New program tracks rare side effects of schizophrenia injection
NCT ID NCT01088386
First seen Feb 01, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This program monitors 4000 people with schizophrenia who receive Zyprexa Relprevv, a long-acting injection. The goal is to track and reduce the risk of a rare but serious reaction called post-injection delirium/sedation syndrome (PDSS). Researchers will record how often PDSS happens and look for possible risk factors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
United BioSource Corporation
Blue Bell, Pennsylvania, 19422, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
olanzapine pamoate (Zyprexa Relprevv)
What this could lead to
If successful, this program could help make Zyprexa Relprevv safer by identifying risk factors and reducing rare but serious post-injection reactions.
What could go wrong
This is an observational safety program, not a test of whether the drug works. It may not change how the drug is used, and rare events may still occur.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.